Latest news

Adalvo announces the successful completion of the Pivotal BE study of Ambrisentan/Tadalafil Film-Coated Tablets 5mg/20mg under Fed and 10mg/40mg under Fasting conditions.   With the successful completion of our initial studies, we...

At Adalvo, we believe in making a positive, sustainable impact on the communities where we live and work. On this World Environment Day, we are proud to highlight our ongoing...

Adalvo is on target to file the Ruxolitinib Immediate Release (IR) Tablets dossier in Q4 2024. Filing upon dossier readiness, Adalvo aims to be among the first companies to launch this...

Adalvo announces the successful DCP approval for Dalbavancin 500mg Powder for concentrate for solution for infusion.  This niche antibiotic has been developed based on the reference brand Xydalba (EU) and is...

Adalvo’s Lisdexamfetamine 10mg/ml Oral Solution has secured approvals in the EU, with US submission upcoming.  To our knowledge, we are the first and only company to secure approval for Lisdexamfetamine...

Adalvo announces positive progress in our Dydrogesterone 10mg tablets project.   Our DCP is in pre-assessment and we are positioned to be one of the first players to secure the first...

Adalvo showcases Mellozzan®, an EU-approved product designed to alleviate both jet lag and ADHD-related insomnia symptoms.   Mellozzan®, which contains the well-established active substance, Melatonin, is available in capsule and oral...

In today's fast-paced world, mental health awareness has become more crucial than ever. At Adalvo, we recognize the importance of fostering a supportive and nurturing environment where our employees' mental...

Adalvo provides an update on Rifamycin SV MMX, an EU-approved product, with Marketing Authorizations (MAs) secured in selective countries.

Adalvo announces the restart of the DCP procedure for Mirabegron 50 mg prolonged-release tablets with an anticipated EU Marketing Authorisation Approval date in July 2024. Developed based on the reference brand...

Diabetic care presents a complex challenge, requiring diverse treatment options to improve patient outcomes effectively.  Adalvo's diabetes portfolio offers advanced therapies designed to address the underlying conditions of the disease. From...

Adalvo announces the restart of the DCP procedure for Desogestrel/Ethinylestradiol 150/20 micrograms film-coated tablets, with an anticipated EU approval date for August 2024.  Developed based on the reference brand Mercilon film-coated tablets,...

In Q1 2024, Adalvo successfully submitted a total of 329 Marketing Authorisation (MA) applications, spanning 55 countries and representing collaborative efforts with 31 strategic partners.  On top of this, Adalvo achieved...

Adalvo acknowledges and participates in World IP Day 2024, joining the global community in celebrating innovation and creativity in intellectual property (IP). This year's theme, "𝐈𝐏 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐒𝐃𝐆𝐬: 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠...

Adalvo is excited to announce the introduction of Apalutamide to our Oncology Portfolio. Based on the reference brand Erleada, Apalutamide, available in film-coated tablet form with strengths of 60mg and 240mg, is a...

Adalvo is strategically advancing in the development of Ceftazidime + Avibactam, a complex and differentiated antibiotic combination, aiming to be First To File in all major markets.  Based on the...

Adalvo proudly announces a significant milestone in its operational performance, setting a new record by releasing a total of 221 batches during March 2024, surpassing previous benchmarks by 42%. This achievement showcases...

Adalvo and Aristo Pharma proudly announce the successful launch of Pregabalin Prolonged Release Tablets in Germany, solidifying their position as the first to introduce this innovative medication in the European...

Adalvo proudly announces the addition of Mirabegron/Solifenacin Prolonged Release Tablets to our product list, set to be submitted for regulatory approval in Q1 2025. Developed in collaboration with one of our strategic...

Aztiq, a prominent healthcare investor led by Founder and Chairman Róbert Wessman, has finalized an agreement in Q1 2024 with Innobic (Asia) Company Limited (“Innobic”), the life science arm of...

Adalvo is pleased to announce the restart of the EU Marketing Authorisation Approval for Empagliflozin 10mg and 25mg film-coated tablets with an anticipated approval date in July 2024. Our product has...